TP与GP方案治疗老年国人晚期非小细胞肺癌疗效Meta分析  

A meta analysis of TP compared with GP in the treatment of Chinese old patients with advanced non-small cell lung cancer

作　　者：唐伏秋[1] 涂颖[1] 赵勇[1] 

机构地区：[1]广州军区武汉总医院,湖北武汉430070

出　　处：《现代中西医结合杂志》2013年第22期2414-2417,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的比较TP和GP方案在治疗老年国人晚期非小细胞肺癌(NSCLC)的治疗效果及安全性,为临床实践与研究提供参考。方法计算机检索Cochrane Library、PubMed、EMBASE和中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊数据库、数字化期刊全文数据库,同时辅以其他检索。纳入TP与GP方案治疗老年晚期NSCLC的随机对照试验(RCT),选择适当的质量评价标准对纳入文献进行质量评价,使用RevMan 5.0软件进行Meta分析。结果共纳入3篇RCT,共293例老年晚期NSCLC患者。Meta分析结果显示:TP和GP方案总有效率(OR=0.93,95%CI:0.59～1.48,P=0.76)、Ⅲ～Ⅳ度白细胞减少率(OR=1.17,95%CI:0.69～1.98,P=0.57)、胃肠道反应的发生率(OR=1.08,95%CI(0.62,1.88),P=0.78)比较无明显差异,但Ⅲ～Ⅳ度血小板减少率比较有明显的差异(OR=0.07,95%CI(0.02,0.30),P=0.000 3),提示TP方案的血小板减少率小于GP方案。结论对于国人老年晚期NSCLC患者,TP与GP方案疗效相当,Ⅲ～Ⅳ度血小板减少发生率,GP高于TP方案,化疗中要密切监测患者的血小板变化。Objective It is to evaluate the efficacy and toxicity of TP compared with GP in the treatment of Chinese old pa- tients with advanced non-small cell lung cancer（NSCLC）. Methods Relevant randomized controlled trials（RCTs） from Co- chrane Library, PubMed, EMBASE and CNKI etc were searched and included. The random-control trails about the treatment for old NSCLC with TP or GP were selected and the quality of these included studies were evaluated by Cochrane Handbook 5. 0, while the datas were analyzed by RevMan 5.0 software. Results Three RCTs involving 293 patients were included. The meta analysis results suggested that compared with GP group, TP group had no significant difference in effective rate（ OR = 0. 93,95 % CI （0.59,1.48）, P = 0.76 ） , leukopenic rate of Ⅲ - Ⅳ degree （ OR = 1.17,95 % CI （ 0.69,1.98 ） , P = 0.57 ）, and gastrointestinal symptom rate （ OR = 1.08,95 % CI （ 0.62,1.88 ） , P = 0.78 ）. Besides, the TP group had a statistically signifi- cant benefit in thrombocytopenic rate of Ⅲ - Ⅳ degree （ OR = 0.07,95% CI （ 0.02,0.30 ） , P = 0. 0003 ）. Conclusion Com- pared with TP, GP regimen of Chinese patients with advanced NSCLC had the same effective rate and survival rate, but the thrombocytopenic rate of Ⅲ - Ⅳ degree was increased. Platelet count should be carefully monitored in GP chemotherapy regi- men of NSCLC.

关 键 词：紫杉醇 吉西他滨 非小细胞肺癌 meta分析 

分 类 号：R734.2[医药卫生—肿瘤]